Methods for determining single nucleotide variations and genotyping

• US 6,458,544 B1
• Filed: 12/01/2000
• Issued: 10/01/2002
• Est. Priority Date: 12/02/1999
• Status: Expired due to Fees

• Current Assignee: Genaissance Pharmaceuticals Incorporated (Abbvie Incorporated)
• Original Assignee: DNA Sciences, Inc. (Abbvie Incorporated)
• Inventors: Miller, Andrew P.
• Primary Examiner(s): Horlick, Kenneth R.
• Assistant Examiner(s): STRZELECKA, TERESA E
• Application Number:
  US09/728,451
• Time in Patent Office: 669 Days
• Field of Search: 435/6, 435/91.1
• US Class Current: 435/6.1
• CPC Class Codes: C12Q 1/6858 Allele-specific amplification
• CPC Class Codes: C12Q 2521/325 Single stranded exonuclease
• CPC Class Codes: C12Q 2525/125 incorporating agents resulting in resistance to degradation
• CPC Class Codes: C12Q 2535/125 Allele specific primer extension
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers

Abstract

The present invention provides methods and kits for determining the identity of a nucleotide at a variant site on a target nucleic acid. The methods begin with the template-dependent amplification of a target sequence under defined conditions to achieve selective incorporation of a nucleotide analog at the variant site. Amplification product is then subjected to limited degradation to create products having allele-specific sizes, which are subsequently separated on the basis of size. Finally, the number of products and their sizes is to assessed to determine the identity of the nucleotide(s) at the variant site and the genotype of the organism from which the target was obtained.

Claims

1. A method for analyzing a variant site in a target nucleic acid, comprising:

(a) amplifying said target nucleic acid by

(i) providing a first and second primer, said first primer being complementary to a segment of a first strand of said target nucleic acid, the 3′

end of said first primer being adjacent to but not overlapping said variant site, said second primer being complementary to a segment of a second strand of said target nucleic acid and including a nucleotide derivative resistant to digestion by a 5′

-3′

exonuclease, said first and second primer flanking said variant site, wherein said variant site is the site at which a first or second base is located; and

(ii) conducting template dependent extension of said first and second primers in the presence of four deoxynucleoside triphosphates (dATP, dTTP, dGTP and dCTP), wherein one of said deoxynucleoside triphosphates is an analog of a natural deoxynucleotide which is resistant to digestion by said 5′

-3′

exonuclease, said deoxynucleotide analog selected to be the complement of said first or second base at said variant site in said second strand, and wherein said target nucleic acid serves as a template such that an amplified double-stranded product is generated;

(b) digesting said double-stranded product with said 5′

-3′

exonuclease to form a digested product having a single-stranded segment;

(c) removing said single-stranded segment with an enzyme that digests single-stranded DNA to produce a blunt end fragment; and

(d) determining the size of said blunt end fragment as an indicator of whether said variant site includes said first or second base.

2. The method according to claim 1, wherein said 3′

end of said first primer extends to and hybridizes with the base immediately 5′

to said variant site.

3. The method according to claim 1, wherein said nucleotide derivative is located at the 5′

end of said second primer.

4. The method according to claim 1, wherein the 3′

end of said first primer and the 3′

end of said second primer are separated by 5 to 1000 bases when both primers are hybridized to their respective strands.

5. The method according to claim 1, wherein said deoxynucleotide analog is selected from the group consisting of a thiol base, an unphosphorylated base, and a boronated analog.

6. The method according to claim 5, wherein said deoxynucleotide analog is a thiol base.

7. The method according to claim 1, wherein said nucleotide derivative is selected from the group consisting of a thiol base, a phosphorylated base, and a boronated analog.

8. The method according to claim 7, wherein said nucleotide derivative is a thiol base.

9. The method according to claim 1, wherein said 5′

-3′

exonuclease is selected from the group consisting of phage T7 gene 6 exonuclease and lambda exonuclease.

10. The method according to claim 1, wherein said enzyme that digests single-stranded DNA is selected from the group consisting of mung bean nuclease and S1 nuclease.

11. The method according to claim 1, wherein said determining step comprises determining the size of a strand of said blunt end fragment by mass spectroscopy.

12. The method according to claim 1, wherein said determining step comprises determining the size of at least one strand of said blunt end fragment by electrophoresis.

13. The method according to claim 12, wherein said determining step comprises analyzing said blunt end fragment by micro-channel electrophoresis.

14. The method according to claim 1, wherein said second primer includes a label.

15. The method according to claim 14, wherein said label is selected from the group consisting of a fluorophore, a chromophore, a radioisotope, a magnetic particle, and a mass label.

16. The method according to claim 15, wherein said label is a fluorescent label.

17. The method according to claim 16, wherein said fluorescent label is selected from the group consisting of fluorescein and fluorescein derivatives, rhodamine and rhodamine derivatives, cyanine and cyanine derivatives, bodipy and naphthylamine and naphythylamine derivatives.

18. The method according to claim 17, wherein said fluorescent label is selected from the group consisting of FAM, TET, JOE, TAMRA, R110, R6G and ROX.

19. The method according to claim 1, wherein said label is attached to the nucleotide located at the 5′

end of said second primer.

20. The method according to claim 1, wherein said target nucleic acid is selected from the group consisting of the gene for cystic fibrosis transmembrane receptor, P53, a cytochrome P450, angiotensinogen, angiotensin converting enzyme, apolipoprotein E, cholesterol ester transfer protein, a dopamine receptor, a serotonin receptor and HIV RT, or fragments thereof which contain said variant site.

21. The method according to claim 14, wherein said determining step comprises denaturing said blunt end fragment to produce a labeled single strand, separating said labeled single strand by gel electrophoresis, and detecting said labeled single strand.

22. The method according to claim 1, wherein said amplifying step, said digesting step, said removing step and said determining step are all performed using a single integrated device.

23. The method according to claim 1, wherein said determining step includes checking for the presence of two different sized fragments, the presence of two different sized fragments being indicative of a heterozygous condition, and the presence of a single sized fragment being indicative of a homozygous condition.

24. The method according to claim 1, wherein

(a) said 3′ end of said first primer extends to and hybridizes with the base immediately 5′

to the variant site;

(b) said 3′

end of said first primer and the 3′

end of said second primer are separated by 5 to 1000 bases once both primers are hybridized to their respective strands;

(c) said nucleotide derivative and said deoxynucleotide analog are thiol bases;

(d) said 5′

-3′

exonuclease is selected from the group consisting of phage T7 gene 6 exonuclease and lambda exonuclease;

(e) said enzyme that digests single-stranded DNA is selected from the group consisting of mung bean nuclease and S1 nuclease;

(f) said second primer includes a fluorescent label; and

(g) said determining step comprises denaturing said blunt end fragment to produce a labeled single-stranded product, separating said labeled single-stranded product by gel electrophoresis, and detecting said labeled single-stranded product.

25. A method for analyzing a first and second variant site in a first and second target nucleic acid, respectively, said method comprising:

(a) amplifying said first and second target nucleic acid by

(i) providing a first upstream and downstream primer pair, said first upstream primer being complementary to a segment of a first strand of said first target nucleic acid, the 3′

end of said first upstream primer being adjacent to but not overlapping said first variant site, said first downstream primer being complementary to a segment of a second strand of said first target nucleic acid and including a nucleotide derivative resistant to digestion by a 5′

-3′

exonuclease, said first upstream and downstream primer flanking said first variant site, wherein said first variant site is the site at which a first or a second base is located;

(ii) providing a second upstream and downstream primer pair, said second upstream primer being complementary to a segment of a first strand of said second target nucleic acid, the 3′

end of said second upstream primer being adjacent to but not overlapping said second variant site, said second downstream primer being complementary to a segment of a second strand of said second target nucleic acid and including a nucleotide derivative resistant to digestion by a 5′

-3′

exonuclease, said second upstream and downstream primer flanking said second variant site, wherein said second variant site includes said first or said second base;

(iii) conducting template dependent extension of said first and second primer pairs in the presence of four deoxynucleoside triphosphates (dATP, dTTP, dGTP and dCTP), wherein one of said deoxynucleoside triphosphates is an analog of a natural deoxynucleotide which is resistant to digestion by said 5′

-3′

exonuclease, said deoxynucleotide analog selected to be the complement of said first or second base at said first and second variant site in said second strand of said first and second target nucleic acid, and wherein said first and second target nucleic acid each serve as a template such that an amplified double-stranded product is generated from each of said first and second primer pair, thus generating a plurality of double-stranded products;

(b) digesting said plurality of double-stranded products with said 5′

-3′

exonuclease to form a plurality of digested products each having a single-stranded segment;

(c) removing single-stranded segments from said plurality of digested products with an enzyme that digests single-stranded DNA to produce a plurality of blunt end fragments; and

(d) determining the size of said plurality of blunt end fragments to determine whether said first and second variant sites include said first or second base.

26. The method according to claim 25, wherein said first downstream primer includes a first label and said second downstream primer includes a second label.

27. The method according to claim 25, wherein said first and second label are selected from the group consisting of a fluorophore, a chromophore, a radioisotope, a magnetic label and a mass label.

28. The method according to claim 27, wherein said first label and said second label are the same.

29. The method according to claim 26, wherein said first label and said second label are different.

30. The method according to claim 29, wherein said first and second label are fluorescent labels.

31. The method according to claim 25, wherein said first and second target nucleic acid are a single nucleic acid and wherein said first and second variant site are different sites on said single nucleic acid.

32. The method according to claim 25, wherein said first and second target nucleic acid are different and wherein said first and second variant site are the same site on said first and second target nucleic acid.

33. A kit for analyzing a variant site in a target nucleic acid, comprising:

(a) a deoxynucleotide analog for use in primer extension reactions which when incorporated into an extension product is resistant to digestion by a 5′

-3′

exonuclease;

(b) said 5′

-3′

exonuclease; and

(c) an enzyme that digests single-stranded DNA.

34. The kit according to claim 33, wherein said deoxynucleotide analog is selected from the group consisting of group consisting of a thiol base, a phosphorylated base and a boronated analog.

35. The kit according to claim 33, wherein said deoxynucleotide analog is a thiol base.

36. The kit according to claim 33, wherein said 5′

-3′

exonuclease is selected from the group consisting of phage T7 gene 6 exonuclease and lambda exonuclease.

37. The kit according to claim 33, wherein said enzyme that digests single-stranded DNA is selected from the group consisting of mung bean nuclease, and S1 nuclease.

38. The kit according to claim 33, further comprising:

(a) a first primer complementary to a segment of a first strand in said target nucleic acid such that the 3′

end of said upstream primer is adjacent to but does not overlap said variant site; and

(b) a second primer complementary to a downstream segment of a second strand of said target nucleic acid and including a nucleotide derivative resistant to digestion by an exonuclease.

39. The kit according to claim 38, wherein said target nucleic is selected from the group consisting of the gene for cystic fibrosis transmembrane receptor, P53, P450, angiotensinogen, angiotensin converting enzyme, apolipoprotein E, cholesterol ester transfer protein, a dopamine receptor, a serotonin receptor and HIV RT, or fragments thereof which contain said variant site.